Skip to main content
. 2018 Nov 19;2018(11):CD012502. doi: 10.1002/14651858.CD012502.pub2

1.31. Analysis.

Comparison 1 Ezetimibe plus other lipid‐modifying drugs vs other lipid‐modifying drugs alone or plus placebo, Outcome 31 Adverse events ‐ cancer (sensitivity analysis: excluding the studies compared ezetimibe plus statins versus double‐dose statins alone).